-
公开(公告)号：US09873684B2
公开(公告)日：2018-01-23
申请号：US14963658
申请日：2015-12-09
Applicant: Genentech, Inc.
Inventor： Mehmet Kahraman , Steven P. Govek , Nicholas D. Smith , Jeffrey H. Hager , Edna Chow Maneval
IPC: C07D405/12 , A61K45/06 , A61K31/397 , A61K9/00 , A61K47/10 , A61K47/14 , A61K47/38 , A61K9/20 , A61K9/48
CPC classification number: C07D405/12 , A61K9/0014 , A61K9/0019 , A61K9/0095 , A61K9/2054 , A61K9/4866 , A61K31/397 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/38 , A61K2300/00
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20170197915A9
公开(公告)日：2017-07-13
申请号：US14972333
申请日：2015-12-17
Applicant: Genentech, Inc.
Inventor： Jun Liang , Daniel Fred Ortwine , Xiaojing Wang , Steven P. Govek , Mehmet Kahraman , Johnny Y. Nagasawa , Nicholas D. Smith , Simon Charles Goodacre , Nicholas Charles Ray
IPC: C07D205/04 , A61K31/404 , A61K45/06 , A61K31/397 , C07D207/04 , A61K31/40 , C07D409/12 , A61K31/4025 , C07D413/12 , A61K31/422 , C07D417/12 , A61K31/427 , C07D401/14 , A61K31/4439 , C07D411/12 , C07D403/12
CPC classification number: C07D205/04 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/5415 , A61K45/06 , C07D207/04 , C07D207/08 , C07D401/14 , C07D403/02 , C07D403/12 , C07D403/14 , C07D409/02 , C07D409/12 , C07D411/02 , C07D411/12 , C07D413/02 , C07D413/12 , C07D417/02 , C07D417/12 , C07D417/14 , C07D493/04 , A61K2300/00
Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US09475798B2
公开(公告)日：2016-10-25
申请号：US14963653
申请日：2015-12-09
Applicant: Genentech, Inc.
Inventor： Steven P. Govek , Mehmet Kahraman , Nicholas D. Smith , Jeffrey H. Hager , Edna Chow Maneval
IPC: C07D405/12 , A61K45/06 , A61K31/397
CPC classification number: A61K31/397 , A61K9/0014 , A61K9/0053 , A61K9/06 , A61K9/08 , A61K9/20 , A61K9/48 , A61K45/06 , C07D405/12
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Abstract translation: 本文描述的是雌激素受体调节剂的化合物。 还描述了包括本文所述化合物的药物组合物和药物，以及使用这种雌激素受体调节剂单独使用并与其它化合物联合用于治疗介导或依赖于雌激素受体的疾病或病症的方法。
-
公开(公告)号：US10053451B2
公开(公告)日：2018-08-21
申请号：US15164102
申请日：2016-05-25
Applicant: Genentech, Inc.
Inventor： Sharada Labadie , Jun Liang , Daniel Fred Ortwine , Xiaojing Wang , Birong Zhang , Nicholas D. Smith , Steven P. Govek , Mehmet Kahraman , Andiliy G. Lai , Johnny Y. Nagasawa , Simon Charles Goodacre , Nicholas Charles Ray
IPC: C07D405/14 , A61K31/497 , A61K31/397 , C07D491/052 , A61K31/4162 , C07D405/12 , A61K31/4439 , A61K31/416 , C07D405/04
CPC classification number: C07D405/14 , A61K31/397 , A61K31/416 , A61K31/4162 , A61K31/4439 , A61K31/497 , C07D405/04 , C07D405/12 , C07D491/052
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US09855270B2
公开(公告)日：2018-01-02
申请号：US14645578
申请日：2015-03-12
Applicant: Genentech, Inc.
Inventor： Jeffrey J. Hager , James D. Joseph , Jing Qian , Nicholas D. Smith , Edna Chow Maneval , Debasish F. Roychowdhury , Lori Friedman , Deepak Sampath
IPC: A61K31/5375 , A61K31/416 , A61K31/4245 , A61K31/428 , A61K31/437 , A61K31/4025 , A61K31/397 , C12Q1/68
CPC classification number: A61K31/5375 , A61K31/397 , A61K31/4025 , A61K31/416 , A61K31/4245 , A61K31/428 , A61K31/437 , C12Q1/6886 , C12Q2600/156
Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
-
Patent Agency Ranking
公开(公告)号：US20150258099A1
公开(公告)日：2015-09-17
申请号：US14645578
申请日：2015-03-12
Applicant: Genentech, Inc.
Inventor： Jeffrey J. Hager , James D. Joseph , Jing Qian , Nicholas D. Smith , Edna Chow Maneval , Debasish F. ROYCHOWDHURY , Lori Friedman , Deepak Sampath
IPC: A61K31/5375 , A61K31/4245 , C12Q1/68 , A61K31/437 , A61K31/4025 , A61K31/397 , A61K31/416 , A61K31/428
CPC classification number: A61K31/5375 , A61K31/397 , A61K31/4025 , A61K31/416 , A61K31/4245 , A61K31/428 , A61K31/437 , C12Q1/6886 , C12Q2600/156
Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
Abstract translation: 本文描述了通过施用雌激素受体调节剂治疗特征在于ESR1基因突变的ER相关疾病状态的方法和组合物。 本文还描述了通过施用雌激素受体调节剂治疗特征在于ESR1基因突变的激素抵抗 - 雌激素受体（ER）阳性乳腺癌的方法。
-
公开(公告)号：US20150258080A1
公开(公告)日：2015-09-17
申请号：US14645585
申请日：2015-03-12
Applicant: Genentech, Inc.
Inventor： Jeffrey J. Hager , Edna Chow Maneval , Nicholas D. Smith , Lori Friedman , Deepak Sampath
IPC: A61K31/4439 , A61K31/553 , A61K31/5377 , A61K31/397 , A61K31/416 , A61K31/4245 , A61K31/428 , A61K31/4025 , A61K45/06 , A61K31/517
CPC classification number: A61K31/4439 , A61K31/397 , A61K31/4025 , A61K31/416 , A61K31/4188 , A61K31/424 , A61K31/4245 , A61K31/428 , A61K31/437 , A61K31/517 , A61K31/5377 , A61K31/553 , A61K45/06 , A61K2300/00
Abstract: Described herein are therapeutic combinations with estrogen receptor modulators for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Abstract translation: 本文描述的是用于治疗介导或依赖于雌激素受体的疾病或病症的雌激素受体调节剂的治疗组合。
-
公开(公告)号：US09845291B2
公开(公告)日：2017-12-19
申请号：US14972333
申请日：2015-12-17
Applicant: Genentech, Inc.
Inventor： Jun Liang , Daniel Fred Ortwine , Xiaojing Wang , Steven P. Govek , Mehmet Kahraman , Johnny Y. Nagasawa , Nicholas D. Smith , Simon Charles Goodacre , Nicholas Charles Ray
IPC: A61K31/397 , C07D205/04 , C07D403/12 , A61K31/404 , A61K45/06 , C07D207/04 , A61K31/40 , C07D409/12 , A61K31/4025 , C07D413/12 , A61K31/422 , C07D417/12 , A61K31/427 , C07D401/14 , A61K31/4439 , C07D411/12
CPC classification number: C07D205/04 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/5415 , A61K45/06 , C07D207/04 , C07D207/08 , C07D401/14 , C07D403/02 , C07D403/12 , C07D403/14 , C07D409/02 , C07D409/12 , C07D411/02 , C07D411/12 , C07D413/02 , C07D413/12 , C07D417/02 , C07D417/12 , C07D417/14 , C07D493/04 , A61K2300/00
Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20160175284A1
公开(公告)日：2016-06-23
申请号：US14972336
申请日：2015-12-17
Applicant: Genentech, Inc.
Inventor： Sharada Labadie , Jun Li , Jun Liang , Daniel Fred Ortwine , Xiaojing Wang , Jason Zbieg , Steven P. Govek , Mehmet Kahraman , Johnny Y. Nagasawa , Nicholas D. Smith
IPC: A61K31/4025 , C07D401/12 , A61K31/4184 , C07D401/14 , A61K31/404 , A61K45/06 , A61K31/397
CPC classification number: A61K31/4025 , A61K31/397 , A61K31/404 , A61K31/4184 , A61K45/06 , C07D311/14 , C07D401/12 , C07D401/14
Abstract: Described herein are compounds that are estrogen receptor modulators of Formula I: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Abstract translation: 本文描述的是作为式I的雌激素受体调节剂的化合物：及其立体异构体，互变异构体或其药学上可接受的盐，以及本文所述的取代基和结构特征。 还描述了包括本文所述化合物的药物组合物和药物，以及使用这种雌激素受体调节剂单独使用并与其它化合物联合用于治疗介导或依赖于雌激素受体的疾病或病症的方法。
-
公开(公告)号：US20160090377A1
公开(公告)日：2016-03-31
申请号：US14963653
申请日：2015-12-09
Applicant: Genentech, Inc.
Inventor： Steven P. Govek , Mehmet Kahraman , Nicholas D. Smith , Jeffrey H. Hager , Edna Chow Maneval
IPC: C07D405/12 , A61K45/06 , A61K31/397
CPC classification number: A61K31/397 , A61K9/0014 , A61K9/0053 , A61K9/06 , A61K9/08 , A61K9/20 , A61K9/48 , A61K45/06 , C07D405/12
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.033 seconds)
